Xilda-M 500 Tablet SR is a fixed-dose combination medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The sustained-release formulation of Xilda-M 500 ensures a gradual release of active ingredients, promoting better tolerability and adherence. This combination is particularly beneficial for patients inadequately controlled on metformin monotherapy, offering complementary mechanisms to achieve improved glycemic control with a lower risk of hypoglycemia. Xilda-M 500 Tablet SR should be used as part of a comprehensive diabetes management plan, including diet and exercise. It is contraindicated in patients with renal impairment, hepatic dysfunction, or hypersensitivity to its components. Regular monitoring of blood glucose levels, renal function, and potential side effects is recommended during therapy. Consult a healthcare professional before initiating treatment with Xilda-M 500 Tablet SR.